Skip to content

This Site is Intended for Healthcare Professionals Only

Search AI Powered

Latest Stories

Pharmacists' confidence diminishes due to mounting financial pressure, Lloyds Bank’s survey reveals

Growing financial pressures has dented pharmacists confidence, despite an anticipated increase in profits in the current year, latest Lloyds Bank Healthcare Confidence Index revealed on Tuesday (November 9).

Though short-term confidence among pharmacists increased for the fifth consecutive year, ticking up from 27 to 29, the sector’s long-term belief fell from -34 to -42.


Martyn Kendrick, UK head of healthcare banking services at Lloyds Bank, said: “While pharmacists’ confidence has declined somewhat, their short-term outlook has improved for another year, painting a picture of a sector that has begun to bounce back.”

He added that “pharmacists have performed an invaluable service during the lockdown, confirming their place at the heart of our communities.”

The index, a survey of pharmacists, GPs and dentists, has run annually since 2011 and gives a detailed overview of the sector.

Short-term optimism

Around 65 per cent of pharmacists expect to grow their profits in the next year while 62 per cent expect that NHS services to patients will improve.

Lockdown has also boosted the potential for pharmacists, with 61 per cent of them saying they would buy or consider buying another pharmacy.

However, a majority of them feel that financial pressures will increase over the next five years, wavering their confidence.

Online competition

Long-term outlook of pharmacists remains negative as “the sector looks for more clarity on the government’s strategy on disease prevention and managing long-term conditions, including how it will be implemented locally,” the report said.

It noted that 44 per cent of the surveyed pharmacists cited “online rivals as a threat,” indicating a change in consumer behavior during the pandemic.

But, return of normal activity will enable pharmacists to offer more clinical services, which would distinguish them from online operators, it said.

Embracing sustainability

The report said that pharmacists remain committed to improve sustainability of their businesses, with 72 per cent saying it is a vital part of their future plans.

They are working on reduction of waste and paper usage by switching to email and text messages.

Acknowledging challenges faced by pharmacists from online pharmacies, Kendrick said that pharmacists now have the opportunity to expand their range of clinical services and drive new income.

He promised that Lloyds Bank would continue to support pharmacists with guidance and products to meet these targets.

Dr Leyla Hannbeck, chief executive officer at the Association of Independent Multiple Pharmacies, also noted that many see “internet pharmacy as a threat to their business.”

She expected this “trend to weaken as bricks and mortar pharmacies become more focused on delivering clinical services.”

Tony Evans, head of pharmacy at Christie & Co, said: “There have undoubtedly been operational challenges, but pharmacists have learnt a lot about their businesses and the changes they’ve implemented over last 18 months have made them even stronger.”

More For You

Over four million flu vaccines across England in the 2024/25 winter flu season.

Over four million flu vaccines across England in the 2024/25 winter flu season.

CCA release

Community pharmacy administered over four million flu vaccines

Community pharmacy administered over four million flu vaccines across England in the 2024/25 winter flu season, the highest outside of the pandemic, according to the Company Chemists’ Association.

This is nearly 10 per cent higher than the number of flu vaccines administered in 2023/24.

Keep ReadingShow less
Chemotherapy-free leukaemia treatment

The trial found that a combination of two cancer drugs, ibrutinib and venetoclax, could perform better than chemotherapy among patients with chronic lymphocytic leukaemia.

iStock

Chemotherapy-free leukaemia treatment shows promise during trial

In a breakthrough in leukaemia research, scientists in the UK have tested a chemotherapy-free approach, involving a combination of targeted drugs, which may offer better outcomes.

The new treatment could radically change the way chronic lymphocytic leukaemia (CLL), the most common form of leukaemia in adults, is treated.

Keep ReadingShow less
Wales ranked worst for second-trimester abortion access in the UK

Each year about 175 women travel from Wales to England for care

Wales ranked worst for second-trimester abortion access in the UK

A leading healthcare charity has revealed that Wales is the worst part of the United Kingdom for allowing surgical abortions for women.

Surgical abortion is the process removing pregnancy from the womb by inducing local anaesthesia, conscious sedation or general anaesthesia.

Keep ReadingShow less
The fund offers £150 per eligible child - for up to three children per household.

The fund offers £150 per eligible child - for up to three children per household.

Charity reopens funding to ease back to school financial pressures for community pharmacists

Community pharmacists struggling with the costs of their children going back to school can apply for funding from The Leverhulme Trade Charities Trust (LTCT)

The Trust is providing up to £100,000 of support to those working in a community pharmacy or are a registered pharmacist or pharmacy technician

Keep ReadingShow less
Germany's BioNTech to buy CureVac to boost cancer research

Both biotech companies have been working for years in the area of mRNA vaccines and treatments

Germany's BioNTech to buy CureVac to boost cancer research

Germany's BioNTech is buying domestic rival CureVac for $1.25 billion, bringing together two pharmaceutical firms specialised in mRNA technology with the goal of advancing cancer treatments.

BioNTech, which developed the first coronavirus vaccine to be approved in the West along with US pharmaceutical giant Pfizer, said the acquisition would "bring together complementary capabilities and leverage technologies".

Keep ReadingShow less